Clinical Update: SNIPR Biome Doses First Human...
Apr. 20, 2022
Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.
Always stay updated with the free CMN Newsletter.
SNIPR Biome
Main focus: Treatment of bacterial infections
Company stage: Pre-clinical
Diseases: Bloodstream infections caused by E. coli, other infections
Genome editing tool: CRISPR-Cas
Funding stage: Private
Location: Copenhagen, Denmark
Website: https://www.sniprbiome.com/
Partners: Novo Nordisk
SNIPR Biome is a Danish, pre-clinical stage company. The company is focused on novel CRISPR-based antibacterial therapies. The company has patents on several CRISPR-Cas technologies including the Cas9, Cas3 and Cas12a enzymes. While SNIPR Biome has not revealed an official pipeline, it has disclosed the use of its DNA-based CRISPR-guided vector platform to generate next-generation antibiotic therapies.
